Abstract
Granisetron (BRL 43694), a selective 5-HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but 1 patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.
| Original language | English |
|---|---|
| Pages (from-to) | 296-7 |
| Number of pages | 2 |
| Journal | Headache |
| Volume | 31 |
| Issue number | 5 |
| Publication status | Published - May 1991 |
Cite this
Couturier, E. G., Hering, R., Foster, C. A., Steiner, T. J., & Clifford Rose, F. (1991). First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache. Headache, 31(5), 296-7.